Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Appointed director
Inv. presentation
Quarterly results
DELCATH SYSTEMS, INC. (DCTH) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/15/2023 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT ™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma HEPZATO KIT is the only FDA approved liver-directed therapy to treat metastatic uveal melanoma Approval includes treatment naïve and previously treated patients and is not limited by HLA genotype Delcath to hold Business Update Call on August 15, 2023 at 8:00 a.m. Eastern Time NEW YORK, August 14, 2023/PRNewswire/ - Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that today the US Food and Drug Administration approved HEPZATO KIT as a liver-directed treatment for adult patients with metastatic uveal melanoma with unresectable hepatic me...",
"Corporate Presentation"
08/09/2023 8-K Quarterly results
Docs: "Delcath Systems Reports Second Quarter 2023 Results and Provides Business Update"
08/04/2023 8-K Regulation FD Disclosure  Interactive Data
06/07/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Delcath Systems Announces Sandra Pennell as Senior Vice President of Finance NEW YORK, June 7, 2023 Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce that the Company has appointed Sandra Pennell as its new Senior Vice President of Finance. Ms. Pennell will also serve as an Executive Officer of the Company and its Principal Accounting Officer and Principal Financial Officer. Ms. Pennell joins the Company with over twenty-years of experience in a variety of financial oversight roles within the biotechnology industry and she will be responsible for managing all the Company's financial affairs, including preparing global financial statements for the guidance of management in accordance wit..."
05/12/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Delcath Systems Provides Business Update and Reports Preliminary First Quarter 2023 Financial Results"
03/29/2023 8-K Quarterly results
03/27/2023 8-K Quarterly results
03/27/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Delcath Systems Announces up to $85 Million Financing"
02/24/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
02/14/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Delcath Systems Announces New Drug Application Resubmission for HEPZATO Kit NEW YORK, February 14, 2023/PRNewswire/ - Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced it submitted a new drug application resubmission to the US Food and Drug Administration for the HEPZATO ™ Kit seeking approval for the treatment of patients with unresectable hepatic-dominant metastatic ocular melanoma . The resubmission is in response to a September 12, 2013 Complete Response Letter from the FDA. The NDA resubmission contains comprehensive data and information to address all issues identified in the CRL. The FDA is expected to determine whether the resubmission constitutes a complete response and is eligible for revi..."
01/23/2023 8-K Other Events  Interactive Data
01/10/2023 8-K Other Events  Interactive Data
01/03/2023 8-K Investor presentation
Docs: "Delcath Systems, Inc. corporate presentation",
"Delcath Systems, Inc. corporate presentation"
12/13/2022 8-K Quarterly results
10/28/2022 8-K Quarterly results
09/12/2022 8-K Investor presentation
Docs: "Delcath Systems, Inc. corporate presentation dated September 2022",
"Delcath Systems, Inc. corporate presentation dated September 2022"
07/20/2022 8-K Quarterly results
06/06/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/29/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Delcath Systems Reports Fourth Quarter and Full-Year 2021 Results and Provides Business Update"
01/06/2022 8-K Termination of a Material Definitive Agreement  Interactive Data
12/02/2021 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Delcath Systems Announces Third Quarter 2021 Results November 9, 2021 NEW YORK, Nov. 09, 2021 — Delcath Systems, Inc. , an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended September 30, 2021. Recent Business Highlights"
10/26/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/18/2021 8-K Termination of a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
08/11/2021 8-K Quarterly results
06/29/2021 8-K Unregistered Sales of Equity Securities
05/12/2021 8-K Quarterly results
05/07/2021 8-K Quarterly results
04/01/2021 8-K Quarterly results
02/26/2021 8-K Quarterly results
12/11/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 9, 2020 DELCATH SYSTEMS, INC. Delaware 001-16133 06-1245881 1633 Broadway, Suite 22C, New York, New York 10019 489-2100 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 ...",
"Underwriting Agreement, among the Company, Canaccord Genuity LLC and Roth Capital Partners, LLC",
"Opinion of McCarter & English, LLP",
"Engagement Letter, between the Company and Canaccord Genuity LLC",
"Amendment to Engagement Letter, between the Company and Canaccord Genuity LLC",
"Delcath Systems Announces Pricing of Public Offering of Common Stock New York, December 9, 2020 - Delcath Systems, Inc. , an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the pricing of an underwritten public offering of 1,460,027 shares of its common stock at a public offering price of $13.25 per share. The gross proceeds of the offering to the Company are expected to be approximately $19.3 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. The closing of the offering is expected to occur on or about December 11, 2020, subject to the satisfaction of customary closing conditions. Delcath intends to use the net proceeds from this offering for the completio...",
"Delcath Systems Announces Completion of Underwritten Public Offering New York, December 11, 2020 - Delcath Systems, Inc. , an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the completion of an underwritten public offering of 1,679,031 shares of its common stock, including 219,004 shares sold pursuant to the full exercise of an option previously granted to the underwriters to purchase additional shares of common stock. All of the shares were offered by Delcath at a price to the public of $13.25 per share. The Company now estimates that the gross proceeds of the offering to the Company are expected to be approximately $22.2 million, before deducting the underwriting discounts and commissions and other estimated o...",
"Limited Waiver, among the Company, Rosalind Master Fund L.P. and Rosalind Opportunities Fund I L.P"
12/08/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 8, 2020 DELCATH SYSTEMS, INC. Delaware 001-16133 06-1245881 1633 Broadway, Suite 22C, New York, New York 10019 489-2100 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 ...",
"Delcath Systems Announces Proposed Public Offering of Common Stock New York, December 8, 2020 - Delcath Systems, Inc. , an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by Delcath. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Delcath also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares sold in the public of..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy